DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sandoz	MAXITROL	dexamethasone; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	050065	NDA	Novartis Pharmaceuticals Corporation	0078-0771-01	3.5 g in 1 TUBE (0078-0771-01)	1972-01-17
Sandoz	MAXITROL	dexamethasone; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	050065	NDA AUTHORIZED GENERIC	A-S Medication Solutions	50090-4435-0	3.5 g in 1 TUBE (50090-4435-0)	1996-02-21
Sandoz	MAXITROL	dexamethasone; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	050065	NDA AUTHORIZED GENERIC	Sandoz Inc	61314-631-36	3.5 g in 1 TUBE (61314-631-36)	1996-02-21
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the supply chain for the combination drug product containing Dexamethasone, Neomycin Sulfate, and Polymyxin B Sulfate. It identifies key active pharmaceutical ingredient (API) and excipient suppliers, manufacturing considerations, and regulatory landscapes impacting availability and cost.

What is the Drug Product?

The drug product is a sterile ophthalmic suspension or solution combining three active pharmaceutical ingredients:

Dexamethasone: A potent corticosteroid used to suppress inflammation.
Neomycin Sulfate: An aminoglycoside antibiotic effective against a broad spectrum of gram-negative bacteria.
Polymyxin B Sulfate: A cyclic polypeptide antibiotic, also primarily targeting gram-negative bacteria.

This combination is typically prescribed for the treatment of ocular inflammation accompanied by bacterial infection.

Who are the Key API Suppliers?

The supply chain for this multi-component drug relies on distinct suppliers for each API.

Dexamethasone API Suppliers

Dexamethasone is a widely manufactured corticosteroid. Several global chemical and pharmaceutical manufacturers produce it.

Key Manufacturers:
- Thermo Fisher Scientific (USA): Offers Dexamethasone as a research chemical and bulk API [1].
- Akorn Inc. (USA): Historically a significant player in generic drug manufacturing, including products containing Dexamethasone [2].
- Vensan Pharmaceuticals (India): A documented supplier of Dexamethasone API [3].
- Divi's Laboratories (India): A large-scale API manufacturer with Dexamethasone listed in its product portfolio [4].
- Siegfried AG (Switzerland): Provides custom manufacturing services for APIs, including corticosteroids like Dexamethasone [5].
Production Scale: Dexamethasone production is mature. Capacity exists globally, with significant manufacturing bases in India and China.

Neomycin Sulfate API Suppliers

Neomycin Sulfate is produced via fermentation by Streptomyces fradiae.

Key Manufacturers:
- Ennore Coke and Chemicals Ltd. (India): Lists Neomycin Sulfate API in its offerings [6].
- Bristol-Myers Squibb (USA): A historical producer of Neomycin Sulfate, often in finished dosage forms, but its API production capabilities are significant [7].
- Orchid Pharma (India): Known for antibiotic API production, likely including Neomycin Sulfate [8].
- Abbott Laboratories (USA): While primarily a finished dosage form producer, global API sourcing and manufacturing are core to their operations.
Production Considerations: Fermentation-based production requires specialized facilities and strict quality control to manage microbial contamination and ensure consistent potency.

Polymyxin B Sulfate API Suppliers

Polymyxin B Sulfate is another fermentation-derived antibiotic, produced by Bacillus polymyxa.

Key Manufacturers:
- Fresenius Kabi (Germany): A significant producer of injectable drugs, including those containing Polymyxin B [9].
- Pfizer Inc. (USA): Has been involved in the production and distribution of Polymyxin B formulations.
- Xellia Pharmaceuticals (Denmark): Specializes in antibiotic APIs, including Polymyxin B Sulfate [10].
- Lianyungang Luyuan Pharmaceutical Co., Ltd. (China): A listed supplier of Polymyxin B Sulfate API.
Production Challenges: Polymyxin B Sulfate production is complex, and its availability has faced periodic challenges due to manufacturing complexities and demand fluctuations [11]. This API is often considered a higher-cost component compared to Dexamethasone.

What are the Key Excipient Suppliers?

Excipients are crucial for the formulation of sterile ophthalmic suspensions and solutions, impacting stability, solubility, and delivery.

Common Excipients:
- Sterile Water for Injection: The primary solvent.
- Preservatives: e.g., Benzalkonium Chloride.
- Tonicity Adjusters: e.g., Sodium Chloride.
- Viscosity Enhancers: e.g., Hydroxypropyl Methylcellulose (HPMC).
- pH Adjusters/Buffers: e.g., Sodium Phosphate, Citric Acid.
- Wetting Agents: e.g., Polysorbate 80.
Major Excipient Manufacturers:
- Ashland Inc. (USA): A major supplier of pharmaceutical excipients, including HPMC and surfactants.
- BASF SE (Germany): Offers a broad range of pharmaceutical excipients.
- Evonik Industries AG (Germany): A leading supplier of specialty chemicals and excipients.
- Roquette Frères (France): Provides excipients derived from plant-based starches.
- DuPont de Nemours, Inc. (USA): Offers polymers and specialty ingredients for pharmaceutical formulations.
Sterility Requirements: Excipients used in ophthalmic preparations must meet stringent sterility and purity standards, often requiring specialized processing or terminal sterilization. This adds complexity and cost to the supply chain.

What are the Manufacturing Considerations?

The manufacturing of sterile ophthalmic suspensions/solutions presents unique challenges.

Sterile Manufacturing Environment: Production must occur in aseptic processing facilities meeting Good Manufacturing Practices (GMP) guidelines (e.g., ISO Class 5 or Grade A environments). This involves validated cleanrooms, specialized equipment, and highly trained personnel to prevent microbial contamination.
Combination Product Complexity:
- API Compatibility: Ensuring the stability and compatibility of all three APIs in a single formulation. Dexamethasone, Neomycin Sulfate, and Polymyxin B Sulfate have different chemical properties that require careful formulation development.
- Particle Size Control (Suspensions): For suspension formulations, precise control of API particle size is critical for efficacy, dissolution, and preventing irritation. Micronization or controlled precipitation techniques may be employed.
- Solubility Management (Solutions): For solution formulations, ensuring adequate solubility of all APIs can be challenging.
Terminal Sterilization vs. Aseptic Processing:
- Aseptic Processing: For heat-sensitive APIs like Neomycin Sulfate and Polymyxin B Sulfate, aseptic processing (filtering sterilized components and assembling in a sterile environment) is generally preferred over terminal sterilization (e.g., autoclaving the final product).
- Terminal Sterilization: Dexamethasone can withstand some heat, but the combination may not. If terminal sterilization is used, it requires validation to ensure it does not degrade the APIs or affect product performance.
Packaging: Ophthalmic products require specialized sterile packaging, typically multi-dose dropper bottles designed to maintain sterility during use. The integrity of the dropper tip and closure system is crucial.

What is the Regulatory Landscape?

The regulatory framework significantly influences API sourcing, manufacturing, and product approval.

Good Manufacturing Practices (GMP): All API and finished product manufacturing sites must comply with cGMP regulations enforced by authorities like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others. This includes stringent quality control, documentation, and validation protocols.
Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents detail the manufacturing process, quality controls, and facilities for an API. Finished product manufacturers reference these DMFs in their drug applications.
Sterility Assurance: Regulatory agencies place a high emphasis on sterility assurance for ophthalmic products. Manufacturers must demonstrate robust sterilization validation and ongoing environmental monitoring.
ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines provide global standards for quality, safety, and efficacy, impacting API impurity profiles, stability testing, and manufacturing process validation.
API Sourcing Audits: Pharmaceutical companies conduct rigorous audits of their API suppliers to ensure compliance with GMP and quality standards. Changes in API suppliers require revalidation and potentially regulatory submissions.
Post-Approval Changes: Any changes to API sources, manufacturing processes, or excipients require assessment for their impact on product quality and may necessitate regulatory notification or approval.

What are the Market Dynamics and Risks?

The market for multi-component ophthalmic drugs is subject to several influences.

Generic Competition: The combination of Dexamethasone, Neomycin Sulfate, and Polymyxin B Sulfate is available as multiple generic products. This leads to price pressure and reliance on cost-effective API sourcing.
API Price Volatility: The prices of Neomycin Sulfate and Polymyxin B Sulfate, in particular, can be subject to fluctuations based on production capacity, raw material costs, and supply chain disruptions.
Supply Chain Vulnerability: The reliance on a limited number of specialized API manufacturers, especially for Polymyxin B Sulfate, creates potential vulnerabilities. Geopolitical events, manufacturing issues, or regulatory actions at a key supplier's facility can impact global availability.
Quality Control Costs: Maintaining the high quality and sterility required for ophthalmic products adds significant costs to manufacturing, including specialized facilities, rigorous testing, and skilled labor.
Emerging Markets: Growth in emerging markets can increase demand for such ophthalmic antibiotics, potentially straining existing supply capacities.

Key Takeaways

The supply chain for Dexamethasone/Neomycin Sulfate/Polymyxin B Sulfate involves distinct API suppliers for each component, with significant manufacturing bases in India and China for Dexamethasone and Neomycin Sulfate, and specialized producers for Polymyxin B Sulfate.
Excipients, particularly those requiring sterile processing, are critical and sourced from global specialty chemical and pharmaceutical ingredient manufacturers.
Sterile manufacturing, stringent quality control, and adherence to GMP are paramount, driving significant production costs and regulatory oversight.
The market is characterized by generic competition, leading to price pressures, and faces risks associated with API price volatility and potential supply chain disruptions, especially for Polymyxin B Sulfate.

Frequently Asked Questions

Which API in the combination is most likely to face supply chain challenges? Polymyxin B Sulfate is generally considered the most susceptible to supply chain challenges due to its complex fermentation-based production and a more concentrated supplier base compared to Dexamethasone or Neomycin Sulfate.
What are the primary regulatory bodies that oversee the manufacturing of these APIs? The primary regulatory bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national health authorities in major markets such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and China's National Medical Products Administration (NMPA).
How does the sterile manufacturing requirement impact the cost of the finished drug product? Sterile manufacturing necessitates specialized, high-cost infrastructure (cleanrooms, validated equipment), rigorous environmental monitoring, specialized personnel training, and extensive quality control testing, all of which significantly increase the overall production cost of the finished drug product.
Are there alternative APIs that could replace Neomycin Sulfate or Polymyxin B Sulfate in this combination for treating bacterial infections? Yes, other antibiotics such as tobramycin, gatifloxacin, or moxifloxacin are used in ophthalmic formulations to treat bacterial infections, sometimes in combination with corticosteroids. However, direct therapeutic substitution would require new drug development and regulatory approval.
What is the typical shelf life for a sterile ophthalmic suspension or solution containing these APIs? The typical shelf life for sterile ophthalmic suspensions and solutions, when stored properly, ranges from 18 to 36 months from the date of manufacture. This is determined by extensive stability testing of the drug product under various conditions.

Citations

[1] Thermo Fisher Scientific. (n.d.). Dexamethasone, C22H29FO5. Retrieved from https://www.thermofisher.com/order/catalog/product/D104

[2] U.S. Food & Drug Administration. (2021, October 26). FDA Drug Shortages. Retrieved from https://www.accessdata.fda.gov/scripts/drugshortages/ (Note: Specific product status may vary and requires direct query)

[3] Vensan Pharmaceuticals. (n.d.). Product List. Retrieved from company website (specific URL not publicly available for direct API sales lists)

[4] Divi's Laboratories. (n.d.). API Product List. Retrieved from https://www.divislabs.com/product-portfolio

[5] Siegfried AG. (n.d.). APIs & Drug Products. Retrieved from https://www.siegfried.ch/en/products-services/apis-drug-products

[6] Ennore Coke and Chemicals Ltd. (n.d.). Pharmaceutical Ingredients. Retrieved from company product catalog (specific API availability often requires direct inquiry)

[7] Bristol-Myers Squibb. (n.d.). Our Medicines. Retrieved from https://www.bms.com/our-medicines.html (Note: Focus is on finished products; API manufacturing is internal or via partners)

[8] Orchid Pharma. (n.d.). Active Pharmaceutical Ingredients (APIs). Retrieved from https://orchidpharma.com/api/

[9] Fresenius Kabi. (n.d.). Products. Retrieved from https://www.fresenius-kabi.com/us/products (Note: Specific API availability not directly listed, focus on finished products)

[10] Xellia Pharmaceuticals. (n.d.). API Portfolio. Retrieved from https://www.xellia.com/our-business/active-pharmaceutical-ingredients-apis/

[11] U.S. Food & Drug Administration. (2019, April 30). FDA Drug Shortages. Retrieved from https://www.accessdata.fda.gov/scripts/drugshortages/ (Note: Historical data indicates Polymyxin B shortages)

Suppliers and packagers for generic pharmaceutical drug: DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE